ScreenerHero

KYTX Kyverna Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · kyvernatx.com
6.170USD+0.16%Mkt Cap: 381.57M $P/E: —

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap381.57M USD
Enterprise Value214.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-161.31M USD
Revenue/Share—
Last Price6.170 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees149
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.94
PEG—
EV/EBITDA-1.36
EV/Revenue—
P/S—
P/B2.29
EPS (TTM)-2.85
EPS (Forward)-3.17
52W Range
5.30010% of range13.67
52W High13.67 USD
52W Low5.300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.45%
ROA-54.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.71M USD
CapEx (TTM)1.13M USD
FCF Margin—
FCF Yield-28.22%
Net Debt-166.43M USD
Net Debt/EBITDA1.06
Balance Sheet
Debt/Equity0.12
Current Ratio9.06
Quick Ratio8.75
Book Value/Sh2.69 USD
Cash/Share3.23 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.40 USD
Upside (mean)+392.7%
Target Range25.00 USD – 33.00 USD
25.00+392.7% to mean33.00
# Analysts5
Ownership
Shares Out.61.84M
Float39.72M
Insiders6.98%
Institutions79.05%
Short Interest
Short Ratio11.7d
Short % Float16.65%
Short % Out.14.18%
Shares Short8.77M
Short (prev mo.)8.50M
Technical
SMA 507.690 (-19.8%)
SMA 2008.337 (-26.0%)
Beta2.06
S&P 52W Chg16.45%
Avg Vol (30d)896.19K
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)30.5
MACD-0.4396
MACD Signal-0.3623
MACD Hist.-0.0774
BB Upper7.984 USD
BB Middle6.958 USD
BB Lower5.932 USD
BB Width29.48%
ATR (14)0.4336 USD
Vol Ratio (20d)0.68x